Supplement
Bitter melon is a gourd whose fruit and extracts contain plant compounds that may influence how the body handles sugar. People mostly look at it for blood sugar in diabetes, but pooled trials found no significant change in fasting glucose or HbA1c, and the evidence is limited. One small 12-week prediabetes trial found better after-meal glucose, while low blood sugar has been reported, including in children.
- Updated
- How we grade
- 5 studies cited
- Best evidence
- Grade B
- Conditions studied
- 2
- Outcomes
- 6
- Graded outcomes
- 0231
Evidence by condition
- Strong
- Moderate
- Limited
- Very limited
| Grade | Outcome | Effect | Size | Studies | People | Studies list |
|---|---|---|---|---|---|---|
| Safety and Tolerability RCTs show good tolerability - adverse events similar to placebo. Common AEs: GI symptoms (nausea, diarrhea, abdominal discomfort), headache. No significant liver enzyme changes in 12-week trials. ALT/AST stable or slightly declined. | Improves (the measure goes up) | Moderate effect | ||||
| Hypoglycemia Risk SAFETY CONCERN: Hypoglycemic coma and convulsions reported in children. Risk increases when combined with diabetes medications. Case reports of serious hypoglycemia. Caution required with concurrent antidiabetic therapy. | Worsens (the measure goes up) | Moderate effect | ||||
| Fasting Blood Glucose Meta-analysis of RCTs: No significant effect on fasting blood glucose vs placebo (MD -0.03, 95% CI -0.38 to 0.31). High heterogeneity among studies. Individual trials show mixed results with some showing reductions and others showing no effect. | NoneNo effect | |||||
| HbA1c Reduction Meta-analysis: No significant effect on HbA1c (MD -0.12, 95% CI -0.35 to 0.11, I²=56%). Short study durations and small sample sizes may explain inconsistent results. Some individual studies report modest HbA1c reductions. | NoneNo effect | |||||
| Postprandial Glucose Korean prediabetes RCT (12 weeks): Improved postprandial glucose levels, possibly via glucagon suppression. More consistent effect than fasting glucose. Long-term cohort studies needed to confirm prophylactic benefits. | Improves (the measure goes down) | Small effect |
| Grade | Outcome | Effect | Size | Studies | People | Studies list |
|---|---|---|---|---|---|---|
| Traditional Use for Metabolic Syndrome Systematic review: Insufficient high-quality evidence to support efficacy for metabolic syndrome parameters. Traditional use widespread but clinical validation lacking. More rigorous trials needed. | Small effect |
Key findings
- Safety and TolerabilityImproves (the measure goes up)
- Hypoglycemia RiskWorsens (the measure goes up)
- Fasting Blood Glucose
Safety notes in the studies
- RCTs show good tolerability - adverse events similar to placebo.
- Risk increases when combined with diabetes medications.
- Caution required with concurrent antidiabetic therapy.
Studies cited
5 studies from PubMed
- Momordica charantia L.-Diabetes-Related Bioactivities, Quality Control, and Safety Considerations
- Hypoglycemic efficacy and safety of Momordica charantia (bitter melon) in patients with type 2 diabetes mellitus
- The effect of bitter melon (Mormordica charantia) in patients with diabetes mellitus: a systematic review and meta-analysis
- Momordica charantia, a Nutraceutical Approach for Inflammatory Related Diseases
- Bitter melon (Momordica charantia): a review of efficacy and safety